Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1023/a:1020068224909 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Investigation of circulating miR-182-3p, miR -382-3p and miR -93, miR -142-3p involved in tamoxifen resistance and sensitivity in luminal-subtype breast cancer patients: a case-control study.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.
Breast cancer (BC) commonly expresses estrogen receptors (ERs); hence, endocrine therapy targeting ERs is considered an effective treatment. Tamoxifen (TAM) resistance is an essential clinical complication leading to cancer progression and metastasis. This study investigated MicroRNAs (miRNAs) potentially implicated in drug resistance (miR-182-3p, miR-382-3p) or sensitivity (miR-93, miR- 142- 3p).
View Article and Find Full Text PDFEstrogen, estrogen receptor and the tumor microenvironment of NSCLC.
Int J Cancer
January 2025
Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Lung cancer remains the foremost cause of cancer-related mortality worldwide. Clinical observations reveal a notable increase in both the proportion and mortality rate among female non-small cell lung cancer (NSCLC) patients compared to males, a trend that continues to escalate. Extensive preclinical research underscores the pivotal role of estrogen in the initiation, progression, prognosis, and treatment response of NSCLC.
View Article and Find Full Text PDFQuantitative expression of estrogen, progesterone and human epidermal growth factor receptor-2 and their correlation with immunohistochemistry in breast cancer at Uganda Cancer Institute.
PLoS One
January 2025
Department of Clinical Support Services, Division of Laboratory and Pathology Medicine, Uganda Cancer Institute, Kampala, Uganda.
Article Synopsis
- This study focused on detecting Estrogen Receptor (ER), Progesterone Receptor (PR), and HER-2 in breast cancer to help categorize the disease and guide treatment choices.
- Researchers compared two preservation methods for breast tissue samples: traditional formalin fixation and RNAlater, utilizing Immunohistochemistry (IHC) and Quantitative Polymerase Chain Reaction (qPCR) for analysis.
- Findings revealed that ER and PR were positive in 60% of samples, while HER-2 was positive in only 25%, with no significant statistical difference between the results from the two preservation methods.
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Background: Estrogens, such as 17β-estradiol, are the primary female sex hormones predominantly synthesized by mature ovarian follicular cells. The natural exhaustion of ovarian follicular cells during menopause causes a rapid decline in endogenous estrogen levels. This decline in estrogen levels is associated with an increase in chronic, age-related pathologies, including inflammation in the brain.
View Article and Find Full Text PDFBasic Science and Pathogenesis.
Alzheimers Dement
December 2024
University of Arizona, Tucson, AZ, USA.
Background: Estrogen is a master regulator of the bioenergetic system in the female brain, exerting broad control over metabolic processes from glucose transport to glycolysis, mitochondrial respiration, and ATP generation. The loss of estrogen during the perimenopausal transition is associated with decline in brain glucose metabolism and mitochondrial function which can contribute to the two-fold greater lifetime risk of Alzheimer's disease in postmenopausal women. While both ERα and ERβ have been reported to mediate E2 regulation of brain bioenergetic function, their cell-type specific contribution to bioenergetic homeostasis has yet to be elucidated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!